⭐ Ratings & Reviews
No reviews yet — be the first!
No reviews yet.
📖 Description
This is our first stock pick in the planned series of analyst reports on undervalued biotechnology stocks trading below $10-15 with potential to double in the next 3-4 years. Each report is 3-4 pages long and written by Dr. Bhavneesh Sharma, MD, MBA (Finance, NYU). The report contains a discounted cash flow evaluation of the Company with an analyst estimate of the fair value per share.